TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03124459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE-083
Description: Part 1 - Recombinant fusion protein. Part 2 - Recombinant fusion protein or buffer solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE-083
Description: Part 1 - Recombinant fusion protein. Part 2 - Recombinant fusion protein or buffer solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE-083
Description: Part 1 - Recombinant fusion protein. Part 2 - Recombinant fusion protein or buffer solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE-083
Description: Part 1 - Recombinant fusion protein. Part 2 - Recombinant fusion protein or buffer solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE-083
Description: Part 1 - Recombinant fusion protein. Part 2 - Recombinant fusion protein or buffer solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Recombinant fusion protein or buffer solution
Study: NCT00430118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asparaginase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asparaginase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asparaginase
Study: NCT01268085

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiation Alert
Description: A radiation safety pop-up alert with a message about the dangers of cumulative ionizing radiation, the patient's cumulative CAT scan history, and the most recent imaging test from any modality of the same body part

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Control with no inverention
Study: NCT03190005

Intervention type: DRUG
Intervention: clopidogrel
Description: routine Dual antiplatelet therapy after stent implantation, then check PRU(platelet reactivity unit)

Intervention type: DRUG
Intervention: clopidogrel
Description: routine Dual antiplatelet therapy after stent implantation, then check PRU(platelet reactivity unit)

Intervention type: DRUG
Intervention: clopidogrel
Description: routine Dual antiplatelet therapy after stent implantation, then check PRU(platelet reactivity unit)

Intervention type: DRUG
Intervention: clopidogrel
Description: routine Dual antiplatelet therapy after stent implantation, then check PRU(platelet reactivity unit)

Intervention type: DRUG
Intervention: clopidogrel
Description: routine Dual antiplatelet therapy after stent implantation, then check PRU(platelet reactivity unit)

Intervention type: DRUG
Intervention: clopidogrel
Description: routine Dual antiplatelet therapy after stent implantation, then check PRU(platelet reactivity unit)

Intervention type: DRUG
Intervention: Placebos
Description: no medication, healthy subjects.
Study: NCT01880814

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Description: Children will first be randomized into Stage 1 of CBT or Caregiver-Child Treatment. Stage 1 will include six sessions. After Stage 1, child's response to treatment will be evaluated. Responders will be re-randomized into Stage 2 of no treatment or continuation of CBT. If randomized to no treatment, termination session will be completed. If randomized to continuation of CBT, the treatment will include six sessions and a termination session. Insufficient responders will be re-randomized into Stage 2 of continuation of CBT or Caregiver-Child Treatment. Stage 2 will include six sessions and a termination session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caregiver-Child Treatment
Description: Children will first be randomized into Stage 1 of CBT or Caregiver-Child Treatment. Stage 1 will include six sessions. After Stage 1, child's response to treatment will be evaluated. Responders will be re-randomized into Stage 2 of no treatment or continuation of Caregiver-Child Treatment. If randomized to no treatment, termination session will be completed. If randomized to continuation of Caregiver-Child Treatment, the treatment will include six sessions and a termination session. Insufficient responders will be re-randomized into Stage 2 of continuation of Caregiver-Child Treatment or CBT. Stage 2 will include six sessions and a termination session.
Study: NCT00252720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: candesartan
Description: 32 mg oral tablet
Study: NCT00578552

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill - non active sugar pill designed to look alike to the gabapentin medication

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin - 1800 mg/day
Description: gabapentin - 1800 mg/day for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin - 2700 mg/day
Description: gabapentin - 2700 mg/day for 12 weeks.
Study: NCT03171285

Intervention type: OTHER
Intervention: Less than 35 years old
Description: Clinical and laboratory evaluations

Intervention type: OTHER
Intervention: Greater than or equal to 35 years
Description: Clinical and laboratory evaluations
Study: NCT00430118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asparaginase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asparaginase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asparaginase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asparaginase

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: asparaginase

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: asparaginase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asparaginase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Study: NCT01827163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: The q 3 week trastuzumab may be started at the last dose of paclitaxel infusion or from 1-3 weeks after the last dose of paclitaxel. Trastuzumab may also be administered at a dose of 6mg/kg during the last dose of paclitaxel in the THL phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Pegfilgrastim SQ is given on day # 2 of each paclitaxel cycle and may be dropped at the last paclitaxel infusion. Filgrastim may be used in lieu of pegfilgrastim at the physician's discretion.
Study: NCT00207688

Intervention type: DRUG
Intervention: Infliximab 5 mg/kg
Description: Patients who received infliximab 5 mg/kg from C0168T37, C0168T46, C0168T72 studies will be observed.

Intervention type: DRUG
Intervention: Infliximab 10 mg/kg
Description: Patients who received infliximab10 mg/kg from C0168T37, C0168T46, C0168T72 studies will be observed.

Intervention type: DRUG
Intervention: Placebo
Description: Patients who received placebo from C0168T37, C0168T46, C0168T72 studies will be observed.
Study: NCT03723993

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Inflated cuff
Description: After patient being draped, applying cuff inflation will be done to the upper arm not having the arterial line inserted of about 200 mmHg or 15 mmHg above patient's systolic pressure 3 cycles 5 minutes each followed by 5 minutes of pressure relieve

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Non inflated cuff
Description: non inflated cuff around the arm for the control group
Study: NCT00723476

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Centered Advanced Care Planning (FCACP) sessions
Description: FCACP will include three 60- to 90-minute weekly sessions. Sessions consisting of structured conversations with HIV infected adolescents, their proxies, and trained facilitators will aim to enhance quality of life by integrating effective end-of-life (EOL) care and minimizing depression and anxiety. The three sessions will consist of a structured EOL survey, an FCACP interview, and a family problem-solving lesson.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health education control sessions
Description: Health education control sessions will include three 60- to 90-minute sessions and will involve adolescents with HIV/AIDS and their proxies. Topics covered during sessions will include developmental history, planning for the future, and safety tips.
Study: NCT00430118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Study: NCT00584025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levetiracetam
Description: 100 - 500mg IV q 15 min

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo equivalent of 100 - 500 mg levetiracetam IV q 15 min
Study: NCT01486147

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual nutrient profiling tool
Description: Shown color coded fiber and protein 2x2 plot, selected fiber and protein ratings from boxes on the plot.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Nutrient ratings table
Description: Showed nutrition information and had to match to fiber and protein ratings from a table.
Study: NCT00352820

Intervention type: BEHAVIORAL
Intervention: Interview
Description: Recorded face-to-face session.

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Written survey lasting approximately 30 minutes.
Study: NCT00766168

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HDS HI 1.54; pahrifocon A
Description: Contact Lens
Study: NCT05480345

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Impedance cardiography
Description: Transthoracic impedance cardiography recorded with ICG monitor (niccomoTM; Medis, Ilmenau, Germany): electrodes attached to both sides of the patient's neck (4 electrodes in total) and along the midaxillary line of the left and right sides of the chest (4 electrodes in total), employing the xyphoid process as a reference line.
Study: NCT00766168

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FluoroPerm 30 RGP; paflufocon C
Description: Contact lens daily wear
Study: NCT02118532

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IN.PACT Admiral Paclitaxel-Eluting Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter
Description: IN.PACT Admiral Paclitaxel-Eluting Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter originally developed, approved and commercialized by Invatec Technology Center GmbH is the investigational medical device used in the study. Medtronic Inc. acquired Invatec on April 21, 2010. Medtronic
Study: NCT03944447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis, Medical
Description: Patients will be given medical cannabis recommendations and certifications commensurate with the state law in which the encounter occurs. The variations in mechanisms between the states for recommending, registering, certifying, and developing mandated treatment plans or doses will be adhered to; however, variations in state law and cannabis programs should not cause variation in the study design because the end-result is still the same with patients being treated with medical cannabis.
Study: NCT02358317

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video Game Motor Training
Study: NCT03541941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Description: Solution of: 266mg of Bupivacaine Liposome Injectable Suspension (Exparel) mixed with 150mg of Bupivacaine Hydrochloride 0.25% expanded with 60cc of Normal Saline (Nacl0.9%) administered intraoperatively through a transversus abdominis plane (TAP) block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hcl 0.25% Inj
Description: Solution of: 150mg of Bupivacaine Hydrochloride 0.25% expanded with 60cc of Normal Saline (Nacl0.9%) administered intraoperatively through a transversus abdominis plane (TAP) block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hcl 0.25% Inj
Description: Solution of: 150mg of Bupivacaine Hydrochloride 0.25% expanded with 60cc of Normal Saline (Nacl0.9%) administered intraoperatively through a transversus abdominis plane (TAP) block

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline administered intraoperatively through a transversus abdominis plane (TAP) block
Study: NCT01393366

Intervention type: OTHER
Group type: OTHER
Intervention: Telephone Intervention
Description: Only for arm AMA, patient will have one phone every week to evaluate physical conditions.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Practice
Description: None, only usual practice.
Study: NCT03974685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTc niacinamide polyethylene glycol bicyclic RGD peptide (99mTc-3PRGD2)
Description: Single dose
Study: NCT00794547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol
Description: Escalating dose of Calcitriol will be infused IV over 1 hour every 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol
Description: In this portion of the study, all patients will get the same dose of calcitriol (determined from the Phase I study) along with the standard chemotherapy
Study: NCT01688609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib ditosylate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo lumpectomy or mastectomy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00318812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heme Iron Polypeptide (Proferrin)
Description: Heme iron polypeptide 11mg po tid for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron sucrose (Venofer)
Description: Iron sucrose infusion IV q month x 6 months
Study: NCT02358317

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sedentary Video Game Training
Study: NCT01883856

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Silicone plate Ahmed Glaucoma Valve (Model FP7)
Description: This intervention is conducted as a surgical intervention.
Study: NCT00430118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cytarabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: daunorubicin hydrochloride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: daunorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Study: NCT02036918

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sipuleucel-T

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sipuleucel-T
Study: NCT01883856

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Porous Plate Ahmed Glaucoma Valve (Model M4)
Description: This intervention is conducted as a surgical intervention.
Study: NCT04391985

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SOF plus (OBV/PTV/r) plus RBV
Description: They were given SOF in a dose of 400 mg/day, and a fixed dose combination of OBV (25 mg), PTV (150 mg), and r (100 mg) taken with food once daily. RBV was supplied in 200 mg capsules, and the recommended dose was 600 mg/ day to reach 1200 mg/day based on patient's body weight and tolerability.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SOF plus (OBV/PTV/r) plus RBV
Description: They were given SOF in a dose of 400 mg/day, and a fixed dose combination of OBV (25 mg), PTV (150 mg), and r (100 mg) taken with food once daily. RBV was supplied in 200 mg capsules, and the recommended dose was 600 mg/ day to reach 1200 mg/day based on patient's body weight and tolerability.
Study: NCT03446144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IONIS-FB-Lrx
Description: Single Dose of IONIS-FB-Lrx administered once weekly for weeks 1-3, and every other week or less frequently until week 70

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (sterline saline 0.9%)
Description: Calculated volume to match active comparator. Administered subcutaneously weekly for weeks 1-3, and every other week or less frequently until week 70
Study: NCT00603642

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneously administered, once a week, for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AMG 531
Description: Subcutaneously administered, once a week, for 12 weeks
Study: NCT01698710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin bound paclitaxel
Description: Albumin bound paclitaxel will be administered into the mucinous cyst of pancreas in endoscopy procedure.
Study: NCT03513445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Morphine, epinephrine, and ropivacaine cocktail will be administered peri-incisionally during lumbar spine surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine
Description: Morphine, epinephrine, and ropivacaine cocktail will be administered peri-incisionally during lumbar spine surgery.
Study: NCT00430118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Study: NCT00648947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel Bisulfate Tablets 75 mg
Description: 75mg, single dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plavix® Tablets 75 mg
Description: 75mg, single dose fasting
Study: NCT01661114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study: NCT01863030

Intervention type: DEVICE
Intervention: Phasix mesh implant
Study: NCT01560767

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Femoral Nerve Block
Description: Under aseptic conditions, the femoral artery will be palpated immediately below the inguinal ligament and nerve stimulation will be used to identify the femoral nerve just lateral to the artery. Once the femoral nerve has been identified the block may be performed in the routine manner, using 30 ml of levobupivacaine 0.25%. The precise technique used will be noted on trial documentation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: peri-articular infiltration
Description: The peri-articular infiltration of multimodal agents will consist of 150 mg of levobupivacaine, 10 mg morphine and 30mg ketorolac diluted in 0.9% saline to make a volume 100 ml. (0.5ml 1:1000 adrenaline will be added to the mixture to reduce blood loss after the operation) Fifty ml of the mixture will be injected into the posterior, medial and lateral soft-tissues just prior to implantation of the TKA components. Care will be taken to avoid excessive infiltration in the area of the common peroneal nerve. Then, while the cement is curing, the anterior soft-tissues including the quadriceps mechanism, the retinacular tissues and the subcuticular tissues will be infiltrated with the remaining 50 ml of peri-articular injection.
Study: NCT01878344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NAC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study: NCT05673317

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breastfeeding at AU Smartphone Application
Description: This is a free Apple-Based Smartphone Application the participant can download. In the application, there is information and tips for breastfeeding success and continuation, as well as information on additional resources both online and in the community as a whole.
Study: NCT04057677

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bed Rest Intervention
Description: The participant will remain in bed rest for 10 days at the clinical research unit at TRI, AdventHealth, Orlando.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bed Rest Intervention
Description: The participant will remain in bed rest for 10 days at the clinical research unit at TRI, AdventHealth, Orlando.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Program
Description: During the first 4 weeks following bed rest, participants will perform a combination of aerobic and resistance exercise training with a certified exercise physiologist 3 days per week at the TRI exercise training facility.